U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07014709) titled 'Impact of GLP-1 Receptor Agonists on Patients With IPMN' on April 30.
Brief Summary: This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their effects on pre-existing pancreatic conditions remain unclear.
The study aims to evaluate whether GLP-1 RA use in IPMN patients is lin...